scholarly article | Q13442814 |
P50 | author | Krzysztof Żmudka | Q68692834 |
Wojciech Szot | Q73728921 | ||
Marcin Majka | Q88841239 | ||
Piotr Musialek | Q92838989 | ||
Lukasz Tekieli | Q114310827 | ||
Mariusz Trystula | Q114310832 | ||
Andrzej Kadzielski | Q114310901 | ||
Robert Paweł Banyś | Q114448943 | ||
Jacek Kijowski | Q116690048 | ||
Piotr Podolec | Q59188258 | ||
Magdalena Kostkiewicz | Q62591429 | ||
P2093 | author name string | Adam Mazurek | |
Danuta Jarocha | |||
Malgorzata Urbanczyk | |||
P2860 | cites work | Stem cell treatment for acute myocardial infarction | Q24203736 |
Use of mesenchymal stem cells for therapy of cardiac disease | Q27003127 | ||
Malignant transformation potentials of human umbilical cord mesenchymal stem cells both spontaneously and via 3-methycholanthrene induction | Q28536701 | ||
Mesenchymal stem cells in the Wharton's jelly of the human umbilical cord | Q30160386 | ||
Meta-Analysis of Cell-based CaRdiac stUdiEs (ACCRUE) in patients with acute myocardial infarction based on individual patient data | Q30896351 | ||
Human umbilical cord tissue-derived mesenchymal stromal cells attenuate remodeling after myocardial infarction by proangiogenic, antiapoptotic, and endogenous cell-activation mechanisms | Q33746675 | ||
Bioartificial heart: a human-sized porcine model--the way ahead | Q34445550 | ||
Safety of cell therapy with mesenchymal stromal cells (SafeCell): a systematic review and meta-analysis of clinical trials | Q34469147 | ||
Randomized transcoronary delivery of CD34(+) cells with perfusion versus stop-flow method in patients with recent myocardial infarction: Early cardiac retention of ⁹⁹(m)Tc-labeled cells activity | Q34544884 | ||
Are serum-free and xeno-free culture conditions ideal for large scale clinical grade expansion of Wharton's jelly derived mesenchymal stem cells? A comparative study | Q34586865 | ||
Changes in immunological profile of allogeneic mesenchymal stem cells after differentiation: should we be concerned? | Q34803754 | ||
[Visualisation of early engraftment of transcoronary applied CD34+ cells in the infarct border zone] | Q80676593 | ||
Early myocardial engraftment of autologous CD34+ cells administered transcoronary via a physiological cell-delivery system | Q81747722 | ||
Transcoronary stem cell delivery using physiological endothelium-targeting perfusion technique: the rationale and a pilot study involving a comparison with conventional over-the-wire balloon coronary occlusions in patients after recent myocardial in | Q83921613 | ||
Experimental cell therapy: the search for the best stem cell continues | Q85815033 | ||
A critical challenge: Dosage-related efficacy and acute complication intracoronary injection of autologous bone marrow mesenchymal stem cells in acute myocardial infarction | Q86733086 | ||
Immune properties of human umbilical cord Wharton's jelly-derived cells | Q34808849 | ||
Stem and progenitor cell-based therapy in ischaemic heart disease: promise, uncertainties, and challenges | Q34981433 | ||
Comparative quantification of the surfaceome of human multipotent mesenchymal progenitor cells. | Q35222594 | ||
Effects of Intracoronary Infusion of Escalating Doses of Cardiac Stem Cells in Rats With Acute Myocardial Infarction | Q35883152 | ||
Comparison of allogeneic vs autologous bone marrow–derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial | Q36603453 | ||
Stem cells for reprogramming: could hUMSCs be a better choice? | Q36683536 | ||
Umbilical cord cells as a source of cardiovascular tissue engineering | Q36712785 | ||
Concise review: human umbilical cord stroma with regard to the source of fetus-derived stem cells | Q36906533 | ||
Anti-donor immune responses elicited by allogeneic mesenchymal stem cells: what have we learned so far? | Q38064659 | ||
The Therapeutic Potential, Challenges and Future Clinical Directions of Stem Cells from the Wharton’s Jelly of the Human Umbilical Cord | Q38066801 | ||
New Frontiers in Regenerative Medicine in Cardiology: The Potential of Wharton’s Jelly Mesenchymal Stem Cells | Q38070807 | ||
Tracking gene and cell fate for therapeutic gain | Q38180960 | ||
Common Expression of Stemness Molecular Markers and Early Cardiac Transcription Factors in Human Wharton's Jelly-Derived Mesenchymal Stem Cells and Embryonic Stem Cells | Q38317834 | ||
Therapeutic potential of human umbilical cord derived stem cells in a rat myocardial infarction model. | Q40230482 | ||
Fever in myocardial infarction: is it still common, is it still predictive? | Q40279771 | ||
FDA regulation of stem-cell-based therapies | Q43719914 | ||
Human umbilical cord perivascular cells exhibit enhanced cardiomyocyte reprogramming and cardiac function after experimental acute myocardial infarction. | Q43765659 | ||
TASTE-less endpoint of 30-day mortality (and some other issues with TASTE) in evaluating the effectiveness of thrombus aspiration in STEMI: not the "evidence" to change the current practice of routine consideration of manual thrombus extraction | Q45037457 | ||
Intracoronary Infusion of Allogeneic Mesenchymal Precursor Cells Directly After Experimental Acute Myocardial Infarction Reduces Infarct Size, Abrogates Adverse Remodeling, and Improves Cardiac Function | Q47236219 | ||
Infarct size determines myocardial uptake of CD34+ cells in the peri-infarct zone: results from a study of (99m)Tc-extametazime-labeled cell visualization integrated with cardiac magnetic resonance infarct imaging | Q47264225 | ||
Dose-dependent contribution of CD34-positive cell transplantation to concurrent vasculogenesis and cardiomyogenesis for functional regenerative recovery after myocardial infarction | Q48619654 | ||
Integration properties of Wharton's jelly-derived novel mesenchymal stem cells into ventricular slices of murine hearts | Q50673940 | ||
Human umbilical cord cells for cardiovascular tissue engineering: a comparative study | Q51699232 | ||
Wharton’s jelly-derived mesenchymal stem cells promote myocardial regeneration and cardiac repair after miniswine acute myocardial infarction | Q53096877 | ||
Effects of intracoronary delivery of allogenic bone marrow-derived stem cells expressing heme oxygenase-1 on myocardial reperfusion injury | Q53152611 | ||
Cardiopoietic Stem Cell Therapy in Heart Failure | Q57779306 | ||
Reply | Q57779316 | ||
Microvascular Obstruction by Intracoronary Delivery of Mesenchymal Stem Cells and Quantification of Resulting Myocardial Infarction by Cardiac Magnetic Resonance | Q61480032 | ||
P433 | issue | 2 | |
P921 | main subject | mesenchymal stem cell | Q1922379 |
acute myocardial infarction | Q18558122 | ||
P304 | page(s) | 100-107 | |
P577 | publication date | 2015-06-22 | |
P1433 | published in | Postępy w Kardiologii Interwencyjnej | Q26853806 |
P1476 | title | Myocardial regeneration strategy using Wharton's jelly mesenchymal stem cells as an off-the-shelf 'unlimited' therapeutic agent: results from the Acute Myocardial Infarction First-in-Man Study | |
P478 | volume | 11 |
Q41015957 | Cardioprotective Effects of Wharton Jelly Derived Mesenchymal Stem Cell Transplantation in a Rodent Model of Myocardial Injury. |
Q58555709 | Cell-Based Therapies for Cardiac Regeneration: A Comprehensive Review of Past and Ongoing Strategies |
Q92394704 | Cellular Therapy for Ischemic Heart Disease: An Update |
Q38610604 | Concise Review: Mesenchymal Stem Cells in Cardiovascular Regeneration: Emerging Research Directions and Clinical Applications. |
Q41691710 | Crosstalk between mesenchymal stem cells and macrophages in inflammatory bowel disease and associated colorectal cancer |
Q26748751 | Mesenchymal stem cells in cardiac regeneration: a detailed progress report of the last 6 years (2010-2015) |
Q89133396 | Retrieval of a periodontally compromised tooth by allogeneic grafting of mesenchymal stem cells from dental pulp: A case report |
Q64947688 | Safety and Efficacy of Adult Stem Cell Therapy for Acute Myocardial Infarction and Ischemic Heart Failure (SafeCell Heart): A Systematic Review and Meta-Analysis. |
Q57301701 | Temporal changes in the pattern of invasive angiography use and its outcome in suspected coronary artery disease: implications for patient management and healthcare resources utilization |
Q90279588 | The Pros and Cons of Mesenchymal Stem Cell-Based Therapies |
Q90615041 | The use of large animals to facilitate the process of MSC going from laboratory to patient-'bench to bedside' |
Search more.